Cambrex, the global contract development and manufacturing organization, announced significant progress in strengthening its active pharmaceutical ingredient (API) manufacturing footprint in both the United States and Europe, setting the stage for future growth in complex drug production and supply chain resilience.
Cambrex confirmed the completion of initial engineering studies for its planned large‑scale API manufacturing plant in Charles City, Iowa, a key milestone in the company’s previously disclosed $120 million investment strategy. The new facility, with an anticipated groundbreaking in late 2026, is expected to support a substantial expansion of manufacturing capabilities, including 140,000 liters of combined large- and mid-scale production capacity.
This expanded capacity will enable Cambrex to address increasing demand for complex chemistries, such as highly potent APIs (active pharmaceutical ingredients) and controlled substances, while reinforcing its position as a trusted partner for global pharmaceutical innovators.
The Charles City expansion will increase large‑scale API manufacturing capacity at the site by 20 percent, reinforcing the company’s ability to respond to customer needs more efficiently. With advanced Hastelloy agitated filter dryers and enhanced reactor systems, Cambrex aims to reduce production timelines and optimize chemical synthesis processes across multiple product lines.
Claudio Russolo, Chief Operating Officer, emphasized that the company’s investments in both the United States and Europe demonstrate a continued commitment to operational excellence. He noted that the Milan, Italy, site, which holds an 80‑year legacy of pharmaceutical support, is undergoing a $30 million expansion to add new analytical development and process R&D capabilities, along with plant upgrades to support future growth in CDMO services.
“Our Milan site has a distinguished history of supporting pharmaceutical development, and expanding these capabilities ensures we remain at the forefront of complex small molecule manufacturing and API innovation,” Russolo said.
The European expansion in Milan is expected to be completed in the second half of 2027, bolstering the company’s development and analytical services ecosystem. Cambrex also acquired additional land at the site to accommodate future growth, reflecting confidence in long‑term demand for outsourced pharmaceutical services.
Cambrex’s ongoing capital investments come amid broader industry trends that emphasize resilient, diversified supply chains for critical pharmaceutical components. With a global network serving clients across North America and Europe, the company’s efforts to scale API manufacturing capabilities support the industry’s push to localize production for key therapies.
In recent years, Cambrex has committed to expanding capabilities across its network, including site enhancements at Charles City in Iowa and High Point in North Carolina. The Charles City facility has been a central focus of growth efforts, drawing additional manufacturing suites to meet rising customer demand for both small molecule and peptide production.
The Charles City site, which spans 45 acres, has evolved into one of the nation’s premier API manufacturing hubs, producing a broad range of APIs and intermediates that include highly potent molecules. The planned “Pharma 5” plant is set to contribute further to this legacy, marking a new chapter in the site’s development.
Cambrex’s expansion strategy also underscores its commitment to scientific innovation. By integrating advanced technologies and scalable production processes, the company is poised to support the development of next‑generation therapies that require sophisticated manufacturing solutions.
Industry analysts have noted that such investments reflect growing demand for flexible, high‑capacity CDMO partners that can accommodate varied therapeutic modalities, including peptide and highly potent API manufacturing. These capabilities are increasingly vital as pharmaceutical companies look to outsource complex synthesis and scale production on a global scale.
Looking ahead, Cambrex’s simultaneous expansion in the United States and Europe reflects a strategic balance between enhancing domestic manufacturing resilience and strengthening its international research and development ecosystem. The company’s global footprint is expected to play a significant role in accelerating time‑to‑market for new medicines and supporting supply chain diversification.
As Cambrex continues to invest in modernizing its manufacturing infrastructure and technology platforms, the company remains committed to meeting evolving customer needs, sustaining competitive advantage, and fostering innovation in API manufacturing and complex small molecule development.
